Back to top

Acadia Pharmaceuticals price target raised to $35 from $32 at Citi

Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $32 and keeps a Buy rating on the shares after the Committee for M...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ACADIA Pharmaceuticals Inc. (ACAD)